KRE: Regional Banks… From Zero to Hero?
Carter Braxton Worth took a swing at the regional banks on Friday's episode of Options Action. At first blush, this caught us by surprise as local banks have been weak…
AAPL: Walls Street Thinks There is a Worm in the Apple
We do not understand why. Let's take that back. We do understand why. Apple pulled guidance for future financial performance. But given the excellent performance this last quarter and the…
SPY: Be Patient, Don’t Be So Quick to Buy the Dip
Risk assets, specifically, stocks, are finally showing signs of stress. Investors have been acting like stocks were safe havens as no matter what the news, share prices, as reflected in…
TM: Toyota Motor
One of the sectors that have gone unnoticed is the automobile sector. Unless you are in the business, you would not know that manufacturers and auto dealers are doing very…
EEM: Emerging Market Equity ETF
The large-cap technology stocks in the US markets have been the place to be for some time now. Secondarily, the best place to be has been large-cap US stocks in…
ADM: Archer Daniels Midland
We have been looking for a way to play the global shortage of food. What shortage, you might ask as this situation is not getting any press these days. This…
BTC: Crypto Comes Alive!
Bitcoin has been in a bearish consolidation pattern ever since the price hit its $20,000 peak in January of 2018. The bulls have tried to stay hopeful, which is very…
SYF: Synchrony Financial: Out of Sync or Just Misunderstood
Every now and again, we like to discuss off the run names in the investment landscape. One of those names is Synchrony Financial. This article is for paid members -…
AXP: American Express Earnings & Value
Shopping from home is the name of the game. Take a walk around your neighborhood, and you will see, and Amazon, FedEx, and UPS delivery trucks out doing their thing.…
AZN: AstraZeneca, A Diversifying Covid Play
Several companies are competing to find a vaccine to combat the SARS-CoV-2 virus. We have talked about a few of the candidates, but not our 2nd favorite play. AstraZeneca. This…